Literature DB >> 15711504

Problems with general anaesthesia for Caesarean section.

G Lyons1, N Akerman.   

Abstract

This has not been a comprehensive review of problems with general anaesthesia for Caesarean section, but major issues have been considered. The old problems are still with us, but their manifestations are perhaps more subtle as anaesthesia has become more sophisticated. Most of the problems are of our own making, but hindsight is only useful if we apply it to the future. Maternal safety is best served by a continuing expansion in the use of regional anaesthesia, but we must prepare for the problems that we create by ensuring that anaesthetists are adequately trained for the occasional general anaesthetic, possibly with more help from simulation.

Mesh:

Year:  2005        PMID: 15711504

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  4 in total

Review 1.  Attenuation of cardiovascular stress response to endotracheal intubation by the use of remifentanil in patients undergoing Cesarean delivery.

Authors:  Marija S Kutlesic; Ranko M Kutlesic; Tatjana Mostic-Ilic
Journal:  J Anesth       Date:  2015-12-29       Impact factor: 2.078

2.  Inhibitory effect of alprostadil against sevoflurane-induced myometrial relaxation in rats.

Authors:  Yayoi Ohashi; Hiroyuki Sumikura; Takeshi Tateda
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

3.  Neonatal effect of remifentanil in general anaesthesia for caesarean section: a randomized trial.

Authors:  Pavlina Noskova; Jan Blaha; Hana Bakhouche; Jana Kubatova; Jitka Ulrichova; Patricia Marusicova; Jan Smisek; Antonin Parizek; Ondrej Slanar; Pavel Michalek
Journal:  BMC Anesthesiol       Date:  2015-03-26       Impact factor: 2.217

4.  Efficacy and safety of remifentanil for analgesia in cesarean delivery.

Authors:  Xuan Zhou; Lian-Jin Jin; Chun-Yang Hu; Meng Chen; Ying Li; Yue-Shun Zhang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.